JOIN OUR CELL & GENE THERAPY ACCELERATOR TO ACCESS PRESEED FUNDING & EXPERT ADVICE!

With access to industry leaders and pre-seed financing, our cell and gene therapy accelerator will make your project VC ready.

MAKE YOUR PROJECT VC READY

The preseed funds and expertise available will allow you to build a superior proof of concept data package, increasing the chances of successful seed financing.

TIMING

12-18 months starting from September 20th 2021

FUNDING

Up to €500k per company including ButterFly Fund’s preseed intervention and potential access to regional non-dilutive R&D grants.

ACCESS TO STATE-OF-THE-ART FACILITIES

Access to the fully equipped ULB Open BioLab and state of the art technology platforms including bioimaging, microscopy, digital pathology, biomedical image analysis, flow cytometry, genomics, transcriptomics, proteomics, metabolomics, animal models.

APPLICATIONS CLOSE ON FRIDAY AUGUST 13TH 2021

PROGRAM START DATE

From September 20th 2021

WHO SHOULD APPLY?

Academic researchers, industry researchers, independent researchers and early stage companies from all over the world looking for a vibrant ecosystem to develop in.

OBJECTIVES

Accelerating the path towards safer and more efficient ex-vivo & in-vivo gene therapeutics by developing targeted gene delivery and gene editing approaches.

APPLICATIONS CLOSE ON FRIDAY AUGUST 13TH 2021

FOR MORE INFORMATION

Visit the Accelerator webpage

PARTNERING ORGANISATIONS

FUNDING

The ButterFly Fund
Wallonie
Sendit Bio

ACADEMIA

ULB
VUB

CMOS

ThermoFisher Scientific
Catalent
Bone Therapeutics
Exothera

BIOTECHS

Genflow Diagnostics
Ncardia
Senda Biopharma

R&D SERVICES

2 Bridge Industrial Biotech
CMMI
Nexelis